Clinical data | |
---|---|
Trade names | Yupelri |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619009 |
License data |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C35H43N5O4 |
Molar mass | 597.760 g·mol−1 |
3D model (JSmol) | |
| |
|
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]
Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]
References
- ↑ "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.
- ↑ Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
- ↑ Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1): 134. doi:10.1186/s12890-020-1156-4. PMC 7216337. PMID 32393215.
External links
- "Revefenacin". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.